Peplogue
Back to Sleep & mood

Tirzepatide

Proven for weight, type 2 diabetes, sleep apnea and heart risk.

A weekly injection that acts like two gut hormones at once, and the best-selling medicine in this book. In a head-to-head trial it beat semaglutide on weight loss. A made by Eli Lilly, also called Mounjaro and Zepbound.

C188H283N45O564,069.6 g/mol39 amino acidsChain only, without the fatty-acid side chain.

What the evidence shows

Weight loss in obesity
Fat & metabolism
Proven
SURMOUNT-1: about 21% average loss at 72 weeks on the top dose, or 22.5% among people who stayed on it.
Type 2 diabetes
Fat & metabolism
Proven
Approved as Mounjaro.
Obstructive sleep apnea with obesity
Sleep & mood
Proven
Approved in the US in December 2024. In SURMOUNT-OSA, breathing pauses fell by 25 to 29 an hour, against about 5 on placebo.
Cardiovascular risk in type 2 diabetes
Heart & blood
Proven
In SURPASS-CVOT it matched dulaglutide (hazard ratio 0.92) without clearly beating it. FDA added heart and stroke risk reduction to the Mounjaro label in August 2026.
Heart failure with obesity
Heart & blood
Supported
SUMMIT (731 people): worsening heart failure or cardiovascular death fell 38%.
Fatty liver disease (MASH)
Liver
Supported
In a phase 2 trial MASH cleared in 44% to 62% of people, against 10% on placebo.

Side effects and risks

Serious
Boxed warning for thyroid C-cell tumors, seen in rodents.
Serious
Pancreatitis and gallbladder disease.
Common
Nausea, diarrhea, vomiting and constipation, mostly while the dose is rising.
Common
The US label warns that the contraceptive pill may be less reliable for four weeks after starting and after each dose increase, and advises a backup method. The EU label asks for no change.
Common
Muscle is lost along with fat, and weight returns after stopping.
Common
Low blood sugar when combined with insulin or sulfonylureas.

Who should avoid it: Pregnancy, medullary thyroid cancer or MEN 2 in you or your family, and past pancreatitis unless a specialist agrees.

Athletes: Monitoring. Not prohibited. Listed with semaglutide on the 2027 monitoring program, in and out of competition. USADA advisory on 2027 WADA list, 2026-10

How it works

Where it acts
GIP and GLP-1 receptors in the pancreas, gut, fat tissue and brain.
What it changes
The same effects as GLP-1 drugs, with added GIP signalling. How much each part contributes is still debated.
What people notice
Less hunger and steady weight loss over months. Nausea, diarrhoea or constipation are common early on.

How it is taken

Weekly injection under the skin, starting at 2.5 mg and rising by 2.5 mg no faster than every four weeks to a maintenance dose of 5, 10 or 15 mg. A prescriber sets the schedule.

Getting it in the United States

This describes what people do. It is not advice. The decision is yours.

What users report

Recurring themes in public forum posts, unverified and with no comparison group.

Reported benefits

  • Stronger appetite control than semaglutide for many who switched
  • Faster early loss

Reported problems

  • Stomach upset on dose increases
  • Injection-site reactions
  • Tiredness
  • Cost, and worry about regain after stopping

In line with the head-to-head trial in which tirzepatide beat semaglutide on weight.

More contextCase reports, what public figures say, videos and articles, when options run out and the chemistry

Case reports

From journals, regulators and studies of users. One case proves little.

Mixed resultcase series - 40 people - 2025

The UK regulator received 40 pregnancy-related reports across weight-loss injections. It said they raised no safety signal, but advised effective contraception, and a non-oral method for Mounjaro users because the drug can reduce absorption of the pill.

Source: Pharmaceutical Technology, 2025-06

Harm reportednews-reported case - 2026

Fake high-strength Mounjaro pens carrying a genuine batch number reached patients through a private pharmacy in England. Tests found tirzepatide inside but sterility could not be confirmed. Most complaints were dose knobs coming off. No one was reported to need treatment, and the MHRA rated the risk as low.

Source: MHRA, 2026-02

FDA adverse event reports for compounded GLP-1 drugs

Harm reportedcase series - 2024

By late November 2024 the FDA had received more than 392 adverse event reports for compounded semaglutide and more than 215 for compounded tirzepatide. The agency says the true number is likely higher because most state-licensed pharmacies do not have to report.

Source: FDA, 2024

US poison centre calls on GLP-1 drugs

Harm reportedpoison centre data - 22966 people - 2025

US poison centres logged 22,966 GLP-1 agonist exposure cases from 2019 to 2025, a rise of nearly 1,500 percent in calls. Most were accidental dosing errors. With compounded products, some callers had taken ten times the intended amount after misreading syringe units.

Source: America's Poison Centers, 2025

Acute pancreatitis days after starting branded tirzepatide

Harm reportedcase report - 1 person - 2024

A 59-year-old man with type 2 diabetes was switched from semaglutide to prescribed branded tirzepatide. Within days he had severe abdominal pain and vomiting. Scans showed pancreatitis that worsened in hospital, with ileus and a pleural effusion. Other causes were ruled out. He recovered and stopped the drug.

Source: Cureus, 2024

What experts and influencers say

Recommend17
Mixed view15
Warn against17

Paraphrased from the linked sources.

Judges each peptide separately. He sees no use case for BPC-157: no human evidence, animal data mostly from one lab, and claims that keep widening. He is not a proponent of growth-hormone peptides such as CJC-1295, citing short studies and no long-term safety data. He says elamipretide makes sense only for Barth syndrome, that the risks of melanotan II probably outweigh a cosmetic tan, and that he stopped prescribing bremelanotide. He regards the GLP-1 drugs as clearly effective.

Source: Peter Attia, AMA 83 show notes, 2026

Peter AttiaInstagramMixed view

Physician and podcast host

Said people microdosing semaglutide or tirzepatide are in effect test subjects, because neither the benefits nor the risks of very small doses have been studied.

Source: STAT, 2025-11

Reshma RamachandranWebsiteWarns against

Physician and health services researcher, Yale School of Medicine

Photo source: medicine.yale.edu

Watch and read

Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.

Podcast - Barbell Medicine Podcast - 2 Dec 2025 - 86 min

Episode 377: GLP-1 Anti-Obesity Medications Update-Efficacy, Muscle Risk, and Future

Dr Jordan Feigenbaum, Dr Austin Baraki and Dr Spencer Nadolsky, physicians

An evidence-based update on GLP-1 drugs including tirzepatide: trial results, heart and kidney effects, muscle loss, side effects, plus cost and access questions.

Physicians weigh tirzepatide's real benefits against muscle-loss worries.

When options run out

Uses people turn to when standard treatment has failed.

Add-on to insulin in type 1 diabetes

Who
Adults with type 1 diabetes and obesity, a group excluded from the main trials and with no approved weight drug tested for them.
Evidence
One 24-person, 12-week phase 2 trial: the drug group lost about 9 kg more than placebo, mostly fat, and cut daily insulin by about a third. No ketoacidosis or severe lows, but the trial was too small to settle safety. Durability, ketosis and hypoglycaemia risk are still open.
Route
TIRTLE1 trial (ACTRN12624000111572) with a follow-up study planned. Source says a phase 3 programme is under way.

Source: touchENDOCRINOLOGY, 2025-09

Staying on treatment after price shock

Who
UK private patients who do not qualify for NHS supply and faced a list price rise of up to 170 percent in 2025.
Evidence
Pharmacists reported demand surges before the rise and warned of switching to unregulated products. No outcome data on those who switched or stopped.

Source: Independent Pharmacist, 2025-08

Legal last-resort routes

Expanded access (compassionate use)

For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.

Source: FDA, expanded access for patients

Right to Try

For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.

Source: FDA, Right to Try

Trial finders

Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.

Source: NIH, finding a clinical trial

Personal import for serious conditions

FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.

Source: FDA, personal importation

Patient-specific compounding

When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.

Source: Oregon Board of Pharmacy, Feb 2025

Amino-acid sequence

Water-avoidingWater-lovingPositive chargeNegative chargeStructural

Position 20 carries a fatty-acid side chain. Ringed tiles are amino acids not found in natural proteins.

Questions people ask

Are Mounjaro and Zepbound the same drug?

Yes. Both are tirzepatide from Eli Lilly. In the US, Mounjaro is the diabetes brand and Zepbound the brand for weight and sleep apnea; in the EU and Australia, Mounjaro is also licensed for weight management.

Is tirzepatide better than semaglutide for weight loss?

In a head-to-head trial, tirzepatide beat semaglutide on weight. In SURMOUNT-1, average loss was about 21% at 72 weeks on the top dose, or 22.5% among people who stayed on it.

Does Mounjaro make the birth control pill less effective?

The US label warns that the contraceptive pill may be less reliable for four weeks after starting and after each dose increase, and advises a backup method. The EU label asks for no change.

What are the side effects of tirzepatide?

Nausea, diarrhea, vomiting and constipation are common, mostly while the dose is rising. Serious risks include pancreatitis, gallbladder disease and a boxed warning for thyroid C-cell tumors seen in rodents. Muscle is lost along with fat, and weight returns after stopping.

How much does Zepbound cost without insurance?

The maker's US self-pay price in October 2026 was $299 to $449 a month if each refill came within 45 days, and up to $699 otherwise. Compounded versions are still sold, though large-scale compounding lost its legal basis when the shortage ended.

Your notebook

Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.

Start tracking

Sources

  1. AJMC: FDA expands tirzepatide label for cardiovascular risk (28 Aug 2026)
  2. Eli Lilly: second-quarter 2026 results
  3. EMA: Mounjaro product page
  4. NHS South West London: GLP-1 medicines policy (June 2026)
  5. Lilly: Zepbound self-pay prices
  6. Finnrick: vendor test counts

Structure: PubChem